- Trials with a EudraCT protocol (6)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
6 result(s) found for: CPG site.
Displaying page 1 of 1.
EudraCT Number: 2020-004272-17 | Sponsor Protocol Number: CLO-SCB-2019-003 | Start Date*: 2021-03-25 | |||||||||||
Sponsor Name:Clover Biopharmaceuticals AUS Pty Ltd | |||||||||||||
Full Title: A Double-blind, Randomized, Controlled, Phase 2/3 Study to Evaluate the Efficacy, Immunogenicity, and Safety of CpG 1018/Alum-Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (S... | |||||||||||||
Medical condition: SARS-CoV-2-mediated COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-004007-64 | Sponsor Protocol Number: 111476 | Start Date*: 2009-07-16 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: An open, single-arm trial to assess the clinical activity of recMAGE-A3 + AS15 in patients with unresectable MAGE-A3-positive metastatic cutaneous melanoma | ||
Medical condition: First-line treatment for patients with unresectable, MAGE-A3-positive stage III or stage IVa melanoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) IE (Completed) FR (Completed) ES (Completed) IT (Completed) FI (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-001159-20 | Sponsor Protocol Number: STH14404 | Start Date*: 2008-09-25 | ||||||||||||||||
Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust | ||||||||||||||||||
Full Title: A Prospective, Multi-centre, Single-Arm, Open Label Study of the Long term Use of a LHRH Agonist (Decapeptyl® SR, 11.25 mg) in Combination with Livial® Add-back Therapy in the Management of Chronic... | ||||||||||||||||||
Medical condition: Chronic cyclical pelvic pain | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2005-004555-35 | Sponsor Protocol Number: A8501001 | Start Date*: 2005-12-15 |
Sponsor Name:Pfizer Inc | ||
Full Title: International, randomized, open-label, Phase 3 trial of paclitaxel/carboplatin plus PF-3512676 versus paclitaxel/carboplatin alone as first-line treatment of patients with advanced non-small cell l... | ||
Medical condition: First line treatment of chemotherapy-naive patients with locally advanced (Stage IIIB with pleural effusion) or metastatic (Stage IV) Non Small Cell Lung Cancer (NSCLC) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) ES (Completed) HU (Prematurely Ended) CZ (Prematurely Ended) DE (Prematurely Ended) SE (Prematurely Ended) BE (Completed) PT (Prematurely Ended) GR (Prematurely Ended) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2005-004557-10 | Sponsor Protocol Number: A8501002 | Start Date*: 2006-02-21 |
Sponsor Name:Pfizer Inc | ||
Full Title: International, randomized, open-label, Phase 3 trial of gemcitabine/cisplatin plus PF-3512676 versus gemcitabine/cisplatin alone as first-line treatment of patients with advanced non-small cell lun... | ||
Medical condition: First line treatment of chemotherapy-naive patients with locally advanced (Stage IIIB with pleural effusion) or metastatic (Stage IV) Non Small Cell Lung Cancer (NSCLC) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) SK (Completed) ES (Completed) HU (Prematurely Ended) CZ (Prematurely Ended) DE (Prematurely Ended) AT (Completed) PT (Prematurely Ended) BE (Completed) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2009-016636-13 | Sponsor Protocol Number: 113173 | Start Date*: 2010-06-28 | |||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | |||||||||||||
Full Title: An open, dose-escalation Phase I/II study to assess the safety, immunogenicity and clinical activity of recPRAME + AS15 Antigen-Specific Cancer Immunotherapeutic as first-line treatment of patients... | |||||||||||||
Medical condition: First-line treatment of patients with PRAME-positive unresectable stage III or IV metastatic melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
